Your session is about to expire
← Back to Search
Combination therapy dose expansion in ovarian cancer for Prostate Cancer
Study Summary
This trial will evaluate the safety and effectiveness of a new drug (TNG348) and its combination with another drug (olaparib) to treat certain types of cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is enrollment to this research study still available for participants?
"Yes, this clinical trial is currently accruing participants. Clinicaltrials.gov states that the initial post was made on December 8th 2023 and it has been revised as recently as 11 days ago."
How many participants are taking part in this experiment?
"Indeed, the information accessible on clinicaltrials.gov demonstrates that this trial has been recruiting since December 8th 2023 and is in need of 140 participants at a single location."
What are the prime goals of this clinical experiment?
"This 21 day clinical trial seeks to gauge the antitumor efficacy of TNG348 through RECIST 1.1 (Phase 2 only). Secondary objectives include measuring ubPCNA levels in both tumor tissue and blood, assessing single agent or combination anti-tumor activity via RECIST 1.1 per investigator assessment, and characterizing plasma PK profile with an eye towards calculating half-life for this particular medication."
Share this study with friends
Copy Link
Messenger